AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia
MLN4924, Nedd8-activating enzyme inhibitor, is administered intravenously on days 1, 3 and 5 of a 21 day cycle in patients with AML and high-grade myelodysplastic syndrome.
RO5045337 is MDM2 antagonist. It prevents MDM2 protein binding to the tumor suppressor protein p53, restoring so the activity of p53 and the p53 mediated tumor cell death. RO5045337 is administered orally with subcutaneous Cytarabine in patients with acute myelogenous leukemia (AML).